🔴 Outlook Therapeutics is trading 5% down today with no clear catalyst

Outlook Therapeutics is trading 5.22% down at $1.09 after no new company-specific announcement was identified for August 11, 2026.

• The July 24 FDA approval of LYTENAVA remains a significant backdrop.
• Third-quarter fiscal 2026 results are scheduled for August 14, but neither item directly explains today’s decline; broader markets are nearly flat, so the specific cause remains unclear.